Pim-1 Kinase Protects P-Glycoprotein from Degradation and Enables Its Glycosylation and Cell Surface Expression

Yingqiu Xie(Nazarbayev University), Maria R. Baer(University of Maryland, Baltimore), Mehmet Burcu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Douglas E. Linn(University of Maryland, Baltimore), Yun Qiu(University of Maryland, Baltimore)
Molecular Pharmacology
May 12, 2010
10.1124/mol.109.061713
Cited by 95

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
|Journal of Clinical Oncology|2012|408